Previous editions of BioBucks

Roivant finally has something to sell, and Genentech pays up for the payload after next.

Revolution's review clock ran fast, Biohaven's ran out of patience at $795M.

Plus: Zymeworks banks $250M and falls 7%. Bristol Myers walks.

Alzheimer's gets a blood test, Regenxbio gets five bad MRIs, Munich opens Friday.

Non-incretin obesity, a GOP letter aimed at China trial data, and Capricor’s PDUFA comes and goes.

Roche commits $750M to a plant that won't fill a syringe until 2031.

Moderna adds $44B of market cap in a session, and the FDA hands out two firsts.

Overton heads for a Senate fight, and a third China trial death surfaces.

Duravyu's primary miss, a PD-1/VEGF curve that shrank, and AstraZeneca finally printing a win.

Capricor doubles on an FDA reprieve, and Redx backs into Nasdaq with $125M.

Zipalertinib clears Phase 3, and the FDA puts a price on where you run Phase 1.

Plus: PTC raids the Sangamo estate for $111M, and Vykat XR draws heat.

Three drugmakers take Illinois to court, and crossover money backs an FSHD editor.

Jazz swings for rare epilepsy, Trump targets childhood shots, and Sionna hands Vertex a free pass.

Grail's failed test finally gets a date with an FDA panel.

Two rejections, one adcomm, one approval — plus $450M for a drug that reads out in 2029.

Reuters says the AstraZeneca-Bristol Myers talks are off. Also: two IPOs price.

Hinge expands into digestive care, Gilead's Yeztugo beats, and Merck leans harder into the Keytruda combo play.

Curium takes Lantheus private, Pathos writes a $125M check, and Jazz raises the year.

Novo’s ZEUS misses on 6,300 patients. Apnimed’s debut pops 56%.

FDA advisers back Replimune, Alnylam gets cut down to size, and the first pharma tariffs skip their Friday deadline.

J&J swings for Sail, Capricor gets a 9-3 adcomm rebuke, and reverse mergers still find $478M.

J&J writes a $5.5B cheque to close the talc book, Altimmune's GLP-1 lands in the drinking clinic, and Yokohama sells out before it opens.

An OS win and a rare-disease faceplant for AstraZeneca, an FDA ambush on Capricor a day before its panel, and MapLight's 66% haircut on the Cobenfy comp.

argenx bags an anti-CD122 antibody for $2.2B, and CHMP splits its rare-disease verdicts.